The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

Schmitz, Susanne; Maguire, Áine; Morris, James; Ruggeri, Kai; Haller, Elisa; Kuhn, Isla; Leahy, Joy; Homer, Natalia; Khan, Ayesha; Bowden, Jack; Buchanan, Vanessa; O’Dwyer, Michael; Cook, Gordon; Walsh, Cathal

doi:10.1186/s12874-018-0509-7

Table 1 Study characteristics of trials included in the analysis

From: The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

Authors	Treatment	N	Median PFS (months)	Median Age (years)	Median number of previous lines	Mean baseline disease stage^b	Female (%)
RCT trials
Chanan-Khan et al. [48]	1. ob7mg + dex40mg	110	3.09	62	3	2.6	46
Chanan-Khan et al. [48]	2. dex40mg	114	3.55	62	3	2.6	46
Chiou et al. [49]	1. thal100mg + IFN	16	1.5	63^c	1	NR	14
Chiou et al. [49]	2. thal100mg	12	7.9	63^c	1	NR	14
Dimopoulos et al. [50]	1.bor1.3 mg/m2 + vor400mg	317	7.63	62	2	1.9	41
Dimopoulos et al. [50]	2. bor1.3 mg/m2	320	6.83	62	2	1.9	41
Dimopoulos et al. [51]	1. len25mg + dex40mg	176	11.3	63	NR	2.6	41
Dimopoulos et al. [51]	2. dex40mg	175	4.7	63	NR	2.6	41
Dimopoulos et al. [52]	1. carf20mg + dex20mg	464	18.7	65	2	1.8	51
Dimopoulos et al. [52]	2. bor1.3 mg/kg + dex20mg	465	9.4	65	2	1.8	51
Hjorth et al. [53]	1. thal50mg + dex40mg	67	9	71	NR	NR	47
Hjorth et al. [53]	2. bor1.3 mg/m2 + dex20mg	64	7.2	71	NR	NR	47
Kropff et al. [54]	1. dex40mg	126	6	64	1–3 prior lines	1.9	57
Kropff et al. [54]	2. thal100/200/400 mg^a	373	7.4	64	1–3 prior lines	1.9	57
Kropff et al. [55]	1. bor1.3 mg/kg + dex20mg	43	12.6	71	1	2.1	43^d
Kropff et al. [55]	2. bor1.3 mg/kg + dex20mg + cyc50mg	47	9.9	71	1	2.1	43^d
Lonial et al. [56]	1. elo10mg/kg + len25mg + dex40mg	321	19.4	66	2	1.8	40.4^d
Lonial et al. [56]	2.len25mg + dex40mg	325	14.9	66	2	1.8	40.4^d
Moreau et al. [57]	1. ixa4mg + len25mg + dex40mg	360	20.6	66	1	NR	43^d
Moreau et al. [57]	2. len25mg + dex40mg	363	14.7	66	1	NR	43^d
Orlowski et al. [58]	1. sil6mg + bor1.3 mg/m2 + dex40mg	142	8.1	62	1–3 prior lines	NR	NR
Orlowski et al. [58]	2. bor1.3 mg/m2 + dex40mg	144	7.6	62	1–3 prior lines	NR	NR
Orlowski et al. [59]	1. bor1.3 mg/m2	322	6.5	61	NR	NR	44
Orlowski et al. [59]	2. PLD20mg + bor1.3 mg/m2	324	9	61	NR	NR	44
Palumbo et al. [60]	1.elo10mg + bor1.3 mg/m2 + dex20mg	77	9.9	66	1^d	NR	48^d
Palumbo et al. [60]	2. bor1.3 mg/m2 + dex20mg	75	6.8	66	1^d	NR	48^d
Richardson et al. [61]	1. pom4mg	108	2.7	63	5	2.6	46
Richardson et al. [61]	2. pom4mg + dex40mg	113	4.2	63	5	2.6	46
Nagler et al. [62]	1.peri50mg + bor1.3 mg/m2 + dex20mg	69	5.23	NR	1^d	NR	68
Nagler et al. [62]	2. bor1.3 mg/m2 + dex20mg	66	8.29	NR	1^d	NR	68
Richardson et al. [63]	1. bor1.3 mg/m2	333	6.22	61	2	NR	42
Richardson et al. [63]	2. dex40mg	336	3.49	61	2	NR	42
San Miguel et al. [64]	1.pan20mg + bor1.3 mg/m2 + dex20mg	387	12	63	1	1.8	47
San Miguel et al. [64]	2. bor1.3 mg/m2 + dex20mg	381	8.1	63	1	1.8	47
San Miguel et al. [14]	1. pom4mg + dex40mg	302	4	64	5	2	41
San Miguel et al. [14]	2. dex40mg	153	1.9	64	5	2	41
Stewart et al. [65] [65]	1.carf20-17 mg + len25mg + dex40mg	396	26.3	64	2	NR	44
Stewart et al. [65] [65]	2. len25mg + dex40mg	396	17.6	64	2	NR	44
Weber et al. [66]	1. len25mg + dex40mg	177	11.1	63	1–3 prior lines	2.5	40
Weber et al. [66]	2. dex40mg	176	4.7	63	1–3 prior lines	2.5	40
White et al. [67]	1. bor1.3 mg/m2	53	5.1	65	1–3 prior lines	2.1	42
White et al. [67]	2. bor1.3 mg/m2 + bev400mg	49	6.2	65	1–3 prior lines	2.1	42
Hou et al. [68]	1. ixa + len + dex	57	6.7	NR	2	1.7	31
Hou et al. [68]	2. len + dex	58	4.0	NR	2	1.7	31
Dimopoulos et al. [69]	1. dara16mg/m2+ len25mg + dex40mg	286	54.1	65	1	1.7	NR
Dimopoulos et al. [69]	2. len25mg + dex40mg	283	18.4	65	1	1.7	NR
Garderet et al. [70]	1. bor1.3 mg/m2 + thal200mg + dex40mg	135	18.3	61	1	1.6	37
Garderet et al. [70]	2. thal200mg + dex40mg	134	13.6	61	1	1.6	37
Palumbo et al. [71]	1. dara 16 mg/m2 + bor1.3 mg/m2 + dex20 mg	251	18.5	64	2	1.8	43
Palumbo et al. [71]	2. bor1.3 mg/m2 + dex20 mg	247	7.2	64	2	1.8	43
Observational trials
Avet-Loiseau et al. [40]	dex40mg + len25mg	207	9.6	65	3	1.7	44
Chang et al. [41]	bor1.3 mg/m2	65	9.5	54	> = 2	1.3	31
Fukushima et al. [72]	bor1.3 mg/m2 + dex20mg	22	16.8	69	2	2.1	41
Hou et al. [73]	dex20/40 mg + len25mg	199	8.3	60	4	2.8	47
Kneppers et al. [42]	dex40mg + len25mg	117	10	61	3.5	2.7	37
Lacy et al. [74]	dex40mg + pom2mg	34	4.8	62	4	1.7	32
Moore et al. [43]	bor1.3 mg/m2	52	13	72	1	2.6	40
Oehrlein et al. [75]	Dex < 160-480 mg	26	11.6	71	2	2.8	54
Oehrlein et al. [75]	Len10-25 mg	26	11.6	71	2	2.8	54
Pantani et al. [76]	bor1.3 mg/m2 + dex20mg	85	8.7	58	2	2.4	40
Richardson et al. [77]	bor1.3 mg/m2 + dex40mg + pan20mg	55	5.4	61	4	1.9	47
Terpos et al. [78]	dex40mg + thal200mg	35	8	63	2	2.2	34
Walter-Croneck et al. [44]	bor1.3 mg/m2	708	14	60	1	2.1	55

bev bevacizumab, bor bortezomib, carf carfilzomib, cyc cyclophosphamide, dara daratumumab, dex dexamethasone, elo elozumatab, IFN interferon alpha, ixa ixazomib, len lenalidomide, ob oblimersen, pan panobinostat, peri perifosine, PLD pegylated liposomal doxorubicin, pom pomalidomide, sil silituximab, thal thalidomide, vor vorinostat
^aPooled results from 3 arms investigating different doses
^bestimated excluding patients with unknown baseline stage
^cprobably not median but does not state exact method (presumably mean and SD)
^dmedian

Back to article page

ISSN: 1471-2288

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Medical Research Methodology

Contact us